secwatch.observer — SEC 8-K summary
======================================

Issuer:     Adicet Bio, Inc. (ACET)
CIK:        0001720580
Form:       8-K
Filed at:   2026-08-05T20:18:14+00:00
Accession:  0001720580-26-000049
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Adicet Bio Q2 net loss $21.4M; prula-cel Phase 1 update expected 3Q2026 with 22 LN/SLE patients
--------------------------------------------------------------------------------

- Q2 2026 net loss $21.4M ($1.99/share); cash $118.2M sufficient into 2H2027.
- Phase 1 prula-cel update in 3Q2026: 22 LN/SLE patients with ≥6 months follow-up, 13 with ≥12 months.
- FDA alignment on potential pivotal trial design for LN; start-up activities planned 2H2026.
- Regulatory filing for ADI-212 in mCRPC expected 3Q2026; Phase 1 enrollment anticipated 4Q2026.
- Lloyd Klickstein appointed Interim CMO following departure of Dr. Julie Maltzman.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1720580/000172058026000049/0001720580-26-000049-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1720580/000172058026000049/acet-20260805.htm
  HTML page:      https://secwatch.observer/filing/0001720580-26-000049

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer